VIDEO: Evaluating 'biologic foundations' could influence targeted therapies in breast cancer
Click Here to Manage Email Alerts
In this video, Debu Tripathy, MD, discussed abstracts that may influence targeted therapies over the next year presented at the 38th Annual Miami Breast Cancer Conference.
Tripathy, professor and chair of the department of breast medical oncology at the University of Texas MD Anderson Cancer Center and a HemOnc Today Editorial Board member, told Healio that abstracts evaluating tumor biology in addition to pharmacological treatments are areas “important and evolving” in research.
“We know that breast cancers are heterogeneous and we also know that they’re complicated and can develop resistance, so if we can develop tailored combinations based on the biology of these tumors, we may be able to affect more tumor cell kill,” he said. “We may even be able to cross the curability threshold by the intelligent design of combinations that are based on the biologic foundations that we would not have been able to uncover unless we actually did it in the patients that were receiving these therapies.”
Collapse
Read more about
Click Here to Manage Email Alerts